Table 1. Baseline Patient Characteristics (n=484).
| Variable | Early sADT (n=190) | Delayed sADT (n=294) | p value |
|---|---|---|---|
| Age (yr) | 66 (60–71) | 67 (63–70) | 0.217 |
| BMI (kg/m2) | 23.9 (22.2–26.1) | 24.3 (22.6–25.8) | 0.387 |
| Prostate volume measure by TRUS (mL) | 28.5 (23.0–38.0) | 29.0 (24.0–39.0) | 0.461 |
| PSA (ng/mL) | 8.3 (5.9–13.1) | 11.8 (8.0–17.8) | <0.001 |
| PSA (categorical) | <0.001 | ||
| <20 | 174 (91.6) | 230 (78.2) | |
| ≥20 | 16 (8.4) | 64 (21.8) | |
| D'Amico risk classification | <0.001 | ||
| Low | 32 (16.8) | 22 (7.5) | |
| Intermediate | 72 (37.9) | 83 (28.2) | |
| High | 86 (45.3) | 189 (64.3) | |
| Pathologic T stage | 0.323 | ||
| Organ confined (T2) | 63 (33.2) | 85 (28.9) | |
| Non-organ confined (>T2) | 127 (66.8) | 209 (71.1) | |
| Pathologic Gleason score | 0.001 | ||
| <8 | 154 (81.1) | 198 (67.3) | |
| ≥8 | 36 (18.9) | 96 (32.7) | |
| Positive surgical margin | 125 (65.8) | 200 (68.0) | 0.609 |
| PSA at sADT (ng/mL) | 0.12 (0.11–0.15) | 0.50 (0.29–1.26) | 0.021 |
| Type of ADT | 0.073 | ||
| LHRH agonist or antagonist with anti-androgens | 104 (54.7) | 177 (60.2) | |
| LHRH agonist or antagonist only | 64 (33.7) | 72 (24.5) | |
| Anti-androgens only | 22 (11.6) | 45 (15.3) | |
| PSA doubling time at ADT (month) | 3.7 (1.9–7.5) | 3.5 (1.7–6.9) | 0.283 |
| Salvage radiotherapy | 29 (15.3) | 103 (35.0) | <0.001 |
| PSA >0.2 ng/mL after sADT | 47 (24.9) | 175 (59.9) | <0.001 |
BMI, body mass index; LHRH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; sADT, salvage androgen deprivation therapy; TRUS, transrectal ultrasonography.
Data are expressed as median (interquartile range) or n (%).